| Document |
Document Title |
|
WO/2011/029614A1 |
The present invention relates to crystalline modifications of (1R,3R,6R)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cycloh
exane-1,3-diol, (1S,3S,6S)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cycloh
exane-1,3-diol and mixtures thereof, ...
|
|
WO/2011/027359A2 |
The present invention relates to novel process for the preparation of 4-hydroxy Atomoxetine or its pharmaceutically acceptable salts thereof. The present invention also relates to novel intermediates used in the preparation of 4-hydroxy ...
|
|
WO/2011/026314A1 |
The preparation method of tapentadol and intermediates thereof are provided. The intermediates are the compounds represented by formula (II), their enantiomorphs, diastereomers, recemes, salts or the mixture thereof.
|
|
WO/2011/012560A1 |
The invention pertains to high-molecular photoinitiator compounds comprising a photoactive moiety Q and an amine functionality, preferably a tertiary amino group, where the photoactive moiety Q is a benzoyl photoactive moiety.
|
|
WO/2011/013108A1 |
The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharm...
|
|
WO/2011/005959A1 |
Compounds useful in the preparation of telavancin, for example, were prepared. These compounds include decylaminoethanal dialkyl acetals and N-protected decylaminoethanal dialkyl acetals, imidazolidine derivatives, and N-protected- decyl...
|
|
WO/2011/000106A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic ...
|
|
WO/2010/145800A1 |
The present invention relates to tramadol-diflunisal salts, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
|
|
WO/2010/144959A1 |
The present invention relates to analogues of anti-fibrotic agents having the formula (I) with the substituents as described within the specification. The present invention also relates to methods for their preparation.
|
|
WO/2010/139520A1 |
According to the present invention, a method for separating a primary amine being an N,N- dialkylbisaminoalkylether, from mixtures comprising said primary amine and at least one of a secondary amine being an N,N,N'-trialkylbisaminoalkyle...
|
|
WO/2010/139521A1 |
A method for providing a secondary or tertiary amine with formula (R1R2NR3)2NR4 is provided, wherein each of R1 and R2 are chosen from the group consisting of a methyl group, an ethyl group, an iso-propyl group and an n-propyl group; R3 ...
|
|
WO/2010/128270A2 |
The present invention provides treatment fluids useful for subterranean operations, and more particularly, in at least one aspect, a treatment fluid that comprises a carrier fluid and a cationic surfactant comprising a cationic head grou...
|
|
WO/2010/128313A2 |
The present invention relates to a corrosion inhibitor for use in the oil and gas exploration, recovery and processing industries. In particular, the invention relates to a quaternary ammonium compound suitable for use as such a corrosio...
|
|
WO/2010/125923A1 |
Disclosed is a polymer-supported catalyst in which a group 8-11 metal of the periodic table is supported by a polymer carrier represented by formula (1a), preferably a polymer carrier represented by formula (1b). (In the formulae, A repr...
|
|
WO/2010/113939A1 |
Disclosed are a compound which has excellent versatility and stability and is useful as a protecting reagent (anchor) for an amino acid and/or a peptide in the liquid-phase synthesis or the like of a peptide with a carboxamide (-CONHR) a...
|
|
WO2010110352A1 |
A process for producing a carboxylic acid compound, the process being shown by scheme (I).
|
|
WO/2010/103429A1 |
The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R...
|
|
WO/2010/099745A1 |
Preparation methods of rivastigmine tartrate and its intermediate and the intermediate itself are disclosed. More specifically, the intermediate compound [1-(3-benzyloxy-phenyl)-ethyl]-dimethylamine, its preparation method and methods fo...
|
|
WO/2010/100520A1 |
The present invention relates to a process for the preparation of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (3) (where R is OMe, OH), said process comprising the steps of; subjecting a reaction mixture of substituted phenylac...
|
|
WO/2010/100990A1 |
A process of reacting acetophenone with isopropylmagnesium bromide in the presence of zinc chloride, trimethylsilylmethyl- magnesium chloride (TMSCH2MgCl), and lithium chloride. In the process, the formation of a secondary alcohol (reduc...
|
|
WO/2010/094659A1 |
The invention relates to the use of compounds of formula (I), wherein the substituents are described in the description and claims, for the preparation of medicaments for the treatment of psychoses, dysfunction in memory and learning, sc...
|
|
WO/2010/095227A1 |
Disclosed are: novel compounds characterized by being represented by general formulae (1), (5) and (11), respectively, each of which has an excellent inhibitory activity on the binding between IgE and an IgE receptor (FcεRI); an inhibit...
|
|
WO/2010/095714A1 |
Novel compounds having excellent activity of inhibiting binding of IgE to an IgE receptor (FcεRI), characterized by being represented by general formula (1), general formula (5) and general formula (11); inhibitors for binding of IgE to...
|
|
WO/2010/053572A9 |
|
|
WO/2010/081865A1 |
The present invention relates to a method for separating an enantiomer mixture of (R)- and (S)-3-amino-1-butanol possibly protected at the oxygen atom and to a method for producing substantially enantiomer-pure (R)-3-amino-1-butanol that...
|
|
WO/2010/074804A1 |
The present invention relates to linear amine-functionalized poly(trimethylene ether) compositions, and processes to produce these compositions.
|
|
WO/2010/072409A1 |
The present invention describes a new process for optical resolution of [N-[[3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methy
lamine] which is an intermediate in the preparation of ivabradine.
|
|
WO/2010/073714A1 |
A process for producing an organolithium compound which comprises a step in which an aromatic compound or a halogenated unsaturated aliphatic compound is reacted with a lithiating agent at a temperature of -40ºC to 40ºC in the presence...
|
|
WO/2010/074089A1 |
Provided are novel low-molecular compounds which exhibit calcium receptor antagonist activity, and which are highly safe and orally administrable, namely, compounds having general formula (I) or pharmacologically acceptable salts thereof...
|
|
WO/2010/069561A1 |
The present invention relates to co-crystals of tramadol and paracetamol, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
|
|
WO/2010/064871A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells including the same. The organic electroluminescent compound provides superior luminous efficiency and excellent color...
|
|
WO/2010/061366A1 |
A process for preparing bisoprolol comprises reacting oxazolidinone sulphonate with 4-hydroxybenzylaldehyde to form oxazolidinone benzaldehyde, forming oxazolidone benzylalcohol from oxazolidone benzaldehyde, and subsequently reacting ox...
|
|
WO/2010/048715A1 |
The invention relates to gemini surfactants of formula IA wherein A is a core derived from an organic polyhydroxy compound; R1 and R2 are each independently a hydrophobic group; and R3 and R4 are each independently a surfactant head grou...
|
|
WO/2010/050435A1 |
Disclosed is a novel cyclohexylamine derivative containing a phenyl group, which is useful as a novel sigma receptor ligand. Also disclosed is a therapeutic agent for diseases accompanied by central nervous system disorders, which compr...
|
|
WO/2010/046869A2 |
The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R 5, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
|
|
WO/2010/046808A2 |
The present invention relates to a process for the preparation of Venlafaxine Hydrochloride comprising steps of i) treating 4-methoxyphenyl acetonitrile with cyclohexanone in presence of alkali hydroxide and super base to get 1-[cyano (4...
|
|
WO/2010/043180A1 |
Disclosed are ethoxy diphenyl ethane derivates, preparation processes and uses thereof. Diphenyl ethane is chemically modified by ethoxy substituted on the 4'-position of its B aryl ring and is changed into their soluble prodrugs of phos...
|
|
WO/2010/043571A1 |
The present invention describes a novel process for the preparation of optically active (S)-(-)-2-(N-propylamino)-5-methoxytetraline and (S)-(-)-2-(N-propylamino)-5- hydroxytetraline compounds based on the optical resolution of mixtures ...
|
|
WO/2010/043412A1 |
The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatm...
|
|
WO/2010/042998A1 |
The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pha...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/032254A1 |
The present invention provides a process for the preparation of cis(+/-)-2- [(dimethylamino)-methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride using the stable nitrate salt as an intermediate to give a product containing less than 0...
|
|
WO/2010/031719A1 |
The invention relates to a method for the continuous production of an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, and primary...
|
|
WO/2010/029950A1 |
Disclosed are: a process for producing an optically active epoxy compound and an optically active sulfoxide compound; a ligand and a complex for use in the process; and a process for producing the complex. Specifically disclosed are: an ...
|
|
WO/2010/026957A1 |
Disclosed is a water-soluble rotaxane-type fluorescent dye which is highly luminescent and rarely causes photobleaching even when the dye is irradiated with light for a long period. The water-soluble rotaxane-type fluorescent dye is comp...
|
|
WO/2010/021351A1 |
Disclosed is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonistic) activity. Specifically disclosed is a compound represented by general formula (1) [wherei...
|
|
WO/2010/017550A2 |
The present invention provides compounds, or pharmaceutically acceptable salts or analogs thereof, which exhibit anti-tumor activity. The present invention also includes methods for inhibiting the growth of cancer cells by contacting an ...
|
|
WO/2010/017563A1 |
Polymeric ionic liquids, methods of making and methods of using the same are disclosed.
|
|
WO/2010/012471A1 |
The present invention relates to salts of tramadol and ibuprofen, their crystal form, processes for preparation of the same and their uses as medicaments, more particularly for the treatment of pain.
|
|
WO/2010/013809A1 |
Provided are optically active titanium-salan compounds useful for asymmetric epoxidation and a process for efficient production thereof. In isolating an optically active titanium-salan compound useful for asymmetric epoxidation as a di-Î...
|
